Full-Time

Global Downstream Product Manager

Advanced Wound Dressings

Solventum

Solventum

10,001+ employees

Global healthcare company: wound care, dental

No salary listed

Remote in UK + 2 more

More locations: Leicester, UK | Madrid, Spain

Remote

Remote within United Kingdom or Spain; periodic international travel up to 25-30%.

Bachelor's, Master's

Category
Product (1)
Required Skills
Forecasting
Product Management
Data Analysis

Get referred to Solventum

See people who can refer or advise you

Requirements
  • Bachelor’s degree in Marketing, Business, Life Sciences, or a related discipline
  • 8+ years of experience in global or regional downstream marketing, preferably in medical devices or healthcare
  • Proven experience in global commercialization, portfolio management, and cross-functional leadership
  • Demonstrated experience owning marketing budgets and investment decisions
Responsibilities
  • Lead the global downstream marketing strategy for the Advanced Wound Dressings portfolio, aligned with business and portfolio priorities
  • Define and own global positioning, messaging, and value propositions, ensuring clarity, differentiation, and relevance across markets
  • Translate upstream strategy and evidence into actionable commercialization frameworks that guide regional execution
  • Own product life-cycle management, from launch planning through optimization and rationalisation
  • Own the global downstream marketing budget for the AWD portfolio
  • Allocate investments to the highest‑impact activities, balancing growth opportunities, ROI, and financial discipline
  • Make thoughtful, data‑driven trade‑offs in a resource‑constrained environment, maintaining focus on strategic priorities
  • Continuously assess market trends, evolving standards of care, and competitive activity across regions
  • Proactively adapt downstream strategies and priorities based on changing market dynamics
  • Anticipate risks and opportunities to enable timely and informed decision‑making
  • Partner closely with Market Access, Health Economics, and Medical Affairs to ensure value propositions reflect reimbursement and access realities
  • Contribute to the development of evidence‑based, payer‑relevant narratives that support adoption and long‑term portfolio sustainability
  • Lead the development of global commercialization frameworks, launch standards, and core marketing assets
  • Partner with regional marketing teams to enable effective local adaptation while preserving strategic intent
  • Work closely with sales leadership to support strong in‑market execution and customer engagement
  • Partner with Finance and Strategy teams to support annual planning, forecasting, and budget processes
  • Monitor portfolio performance and contribute to business reviews, translating data into clear insights and actions
  • Support continuous improvement of global marketing ways of working
  • Strong resilience and adaptability in a demanding, high‑expectation environment
  • Highly proactive, with the ability to operate with significant autonomy and ownership
  • Comfortable working on a broad, high‑impact portfolio with limited resources, using prioritization and focus to maximize impact
  • Collaborative team player with strong ability to lead through influence in a global matrix
  • Clear communicator, able to simplify complexity and align diverse stakeholders
Desired Qualifications
  • Bachelor’s or Master’s Degree in Business or Marketing
  • Experience working in commercial, marketing or portfolio management roles
  • Previous experience working in the health care industry
  • Experience working across multiple regions and healthcare systems
  • Exposure to market access or reimbursement‑influenced environments

Solventum provides a wide range of healthcare products across four main areas: wound care and surgical supplies, dental and orthodontic tools, health information software, and purification filters for biopharmaceuticals. These products work by combining material science and data science to help hospitals manage patient records, prevent infections during surgery, and filter fluids for medical treatments like dialysis. Unlike many competitors, the company holds a massive portfolio of over 7,300 patents inherited from its history as a 3M division, allowing it to serve over 75% of U.S. hospitals. Its goal is to use this intellectual property and a disciplined business model to find new solutions for healthcare providers and grow within the global medical technology market.

Company Size

10,001+

Company Stage

IPO

Headquarters

Maplewood, Minnesota

Founded

2023

Get referred to Solventum

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Solventum raised 2026 EPS guidance to $7.10-$7.20 after Q2 beat on August 5.
  • Management targets higher-margin MedTech focus after separating HIS and exiting noncore businesses.
  • Thermo Fisher's Purification deal and Acera Surgical acquisition sharpen portfolio and capital allocation.

What critics are saying

  • Q3 2026 revenue will reverse after $125 million ERP pull-forward, compressing growth.
  • HIS separation could fail within 18 months if regulators, boards, or markets balk.
  • AI competitors can undercut HIS workflows; that unit still supplied 16.3% of 2025 sales.

What makes Solventum unique

  • Solventum owns 7,300 patents and 75% U.S. hospital HIS penetration on August 5, 2026.
  • Its wound care and sterilization franchises drove Q2 2026 growth despite ERP disruption.
  • The $200 million Eagan Innovation Hub deepens R&D across MedSurg, dental, and digital health.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Health Savings Account/Flexible Spending Account

Remote Work Options

Paid Vacation

Paid Sick Leave

Paid Holidays

Hybrid Work Options

Relocation Assistance

Growth & Insights and Company News

Headcount

6 month growth

5%

1 year growth

5%

2 year growth

8%
Yahoo Finance
Aug 11th, 2026
Solventum beats Q2 estimates with $2.21B revenue, raises EPS guidance 10% amid HIS separation

Healthcare solutions provider Solventum reported second quarter revenue of $2.21 billion, up 2.2% year on year and ahead of analyst estimates of $2.15 billion. Non-GAAP profit of $2.55 per share beat consensus estimates by 33.8%. The company announced plans to separate its Health Information Systems business to focus on its MedSurg and Dental segments. Management said the move would allow the HIS unit to pursue AI-driven innovation whilst sharpening Solventum's focus as a pure-play MedTech company. Second quarter results were temporarily boosted by approximately $125 million in advanced orders placed ahead of a major ERP system transition, which management expects to reverse next quarter. The company raised its full-year adjusted EPS guidance to $7.15 at the midpoint, a 10% increase. Solventum is nearing completion of its separation from 3M.

Yahoo Finance
Aug 9th, 2026
Solventum raises 2026 outlook with 9.5% Q2 growth boosted by $125M advanced orders and $100M tariff refund

Solventum exceeded expectations in Q2, posting $2.2 billion in sales with 9.5% organic growth. However, this included roughly $125 million in advanced ERP-related orders and a $100 million tariff refund. Excluding these benefits, organic growth was approximately 4% and adjusted EPS was estimated at $1.73. The company raised its 2026 outlook, now expecting 2.5%–3% organic sales growth, a 22.2%–22.7% operating margin, adjusted EPS of $7.10–$7.20, and free cash flow of $200 million–$300 million. Third-quarter growth is expected to decline temporarily as the advanced orders reverse. Solventum also announced plans to separate its Health Information Systems business through a potential spin-off or sale, aiming to focus on its MedSurg and Dental segments.

PR Newswire
Aug 5th, 2026
Solventum Q2 sales up 9.5%, raises 2026 guidance and plans to separate Health Information Systems unit

Solventum reported second quarter 2026 sales of $2.2 billion, up 2.2% on a reported basis and 9.5% organically. The MedTech company posted GAAP diluted earnings per share of $0.53 and adjusted diluted EPS of $2.55, marking a 50.9% increase. Operating cash flow reached $227 million, whilst free cash flow totalled $144 million. The strong performance was driven by volume and product mix across all segments, including advance orders ahead of ERP cutovers. Solventum announced plans to separate its Health Information Systems business segment as part of its transformation strategy. The company raised its full-year 2026 guidance, increasing organic sales growth to 2.5% to 3.0%, adjusted EPS to $7.10 to $7.20, and free cash flow to $200 million to $300 million.

Yahoo Finance
Aug 2nd, 2026
Solventum appoints Neil Zieselman as chief accounting officer

Solventum has appointed Neil Zieselman as Senior Vice President, Controller, and Chief Accounting Officer. He will succeed Mary Wilcox, who is retiring. Zieselman brings experience from Surgery Partners, Stryker Corporation, Covanta Holding Corporation, Cendant Corporation, and Avaya. He is a licensed CPA. The company's stock trades at $85.44. It has delivered a 9.5% return over the past week and 19.1% over the past year. For investors, Zieselman's background in healthcare and corporate finance may influence Solventum's financial controls, reporting quality, and regulatory engagement. His approach could shape disclosure practices and capital allocation commentary in future earnings calls. Interest payments are not well covered by earnings, making any changes under the new Chief Accounting Officer particularly important for risk assessment.

Yahoo Finance
Jun 22nd, 2026
Solventum gains 12% in three months but lags healthcare sector over the year

Solventum, a healthcare company spun off from 3M Company, has underperformed the broader healthcare sector over the past year despite recent gains. The stock trades 14.5% below its 52-week high of $88.20 reached in December 2025. Whilst SOLV shares climbed 12.4% over the past three months compared to the State Street Health Care Select Sector SPDR ETF's 1.5% gain, the longer-term picture shows divergence. Over 52 weeks, Solventum gained 3.9% whilst the healthcare ETF advanced 12.1%. Year-to-date, SOLV has fallen 4.8% versus the sector's 3.5% decline. The company beat Q1 FY2026 expectations on 5 May, with revenue of $2.01 billion and adjusted EPS of $1.48. Management expects nearly 20 new product launches over two years.